140. Back to Basics - Adjuvant HER2 Breast Cancer (Part 2)

HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditional chemotherapy, the landscape of everything we treat is slowly changing. Studies discussed in the episode:KATHERINEPERSEPHONEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.